Jörg Stockhaus
Gründer bei conoGenetix biosciences GmbH
Profil
Jörg Stockhaus is the founder of conoGenetix biosciences GmbH, which was founded in 2002, where he holds the title of Senior Scientist.
Currently, he is a Fellow at The Rockefeller University.
In the past, he held the position of Principal at Aventis Cropscience and Heinrich-Heine-Universität Düsseldorf.
Aktive Positionen von Jörg Stockhaus
| Unternehmen | Position | Beginn |
|---|---|---|
conoGenetix biosciences GmbH
 conoGenetix biosciences GmbH Pharmaceuticals: MajorHealth Technology conoGenetix biosciences GmbH develops peptide-based drugs and new ion channel selective drugs. It runs programs targeting severe autoimmune disorders like multiple sclerosis, rheumatoid arthritis, and vasculitis. The firm development pipeline encompasses peptide design, electrophysiology testing, biophysical parameters and synthesis, proliferation assays, and animal testing and toxicology. The company was founded by Andreas Klostermann, Mira Klostermann and Jörg Stockhaus in March 2002 and is headquartered in Planegg, Germany. | Gründer | 01.03.2002 |
| The Rockefeller University | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Jörg Stockhaus
| Unternehmen | Position | Ende |
|---|---|---|
| Aventis Cropscience | Corporate Officer/Principal | - |
| Heinrich-Heine-Universität Düsseldorf | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
| Aventis Cropscience | Process Industries |
conoGenetix biosciences GmbH
conoGenetix biosciences GmbH Pharmaceuticals: MajorHealth Technology conoGenetix biosciences GmbH develops peptide-based drugs and new ion channel selective drugs. It runs programs targeting severe autoimmune disorders like multiple sclerosis, rheumatoid arthritis, and vasculitis. The firm development pipeline encompasses peptide design, electrophysiology testing, biophysical parameters and synthesis, proliferation assays, and animal testing and toxicology. The company was founded by Andreas Klostermann, Mira Klostermann and Jörg Stockhaus in March 2002 and is headquartered in Planegg, Germany. | Health Technology |
